Barrett's esophagus can progress to esophageal cancer, but it doesn't always. Current treatment is frequent surveillance via upper endoscopy with multiple biopsies to look for changes (dysplasia). Pathologists vary dramatically in their interpretation of Barrett's Metaplasia versus dysplasia and consensus is very difficult to achieve. The investigators propose a longitudinal study of subjects with confirmed Barrett's intestinal metaplasia without dysplasia to look for predictive factors for transformation to dysplasia or cancer. Potential biomarkers can be found in serum, plasma, urine, frozen or fixed Barrett's and Normal esophageal mucosa. In addition, the investigators are testing a brushing technique from CDx, Inc. for predictive factors. Subjects must have pathologically confirmed Barrett's intestinal metaplasia without history of dysplasia to be on this longitudinal study.
Study Type
OBSERVATIONAL
Enrollment
255
Dana Farber Cancer Institute
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Columbia University
New York, New York, United States
Mt. Sinai School of Medicine
New York, New York, United States
MD Anderson Cancer Center
Houston, Texas, United States
St. Michael's Hospital
Toronto, Ontario, Canada
Conversion from Barrett's intestinal metaplasia to dysplasia or esophageal adenocarcinoma.
Time frame: 5-8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.